16 results on '"Takano, Misao"'
Search Results
2. Prevalence of Asymptomatic Mpox among Men Who Have Sex with Men, Japan, January-March 2023
- Author
-
Mizushima, Daisuke, Shintani, Yui, Takano, Misao, Shiojiri, Daisuke, Ando, Naokatsu, Aoki, Takahiro, Watanabe, Koji, Nakamoto, Takato, Gatanaga, Hiroyuki, and Oka, Shinichi
- Subjects
Torii Pharmaceutical Company Ltd. ,Medical research ,Medicine, Experimental ,Infection ,Disease transmission ,Public health ,Pharmaceutical industry ,Health - Abstract
During the 2022 global mpox outbreak, asymptomatic monkeypox virus (MPXV) infections or unrecognized mpox cases were reported among men who have sex with men (MSM) (1-4). Asymptomatic cases were diagnosed [...]
- Published
- 2023
- Full Text
- View/download PDF
3. A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo
- Author
-
Mizushima, Daisuke, Takano, Misao, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Aoki, Takahiro, Watanabe, Koji, Ishizuka, Naoki, and Oka, Shinichi
- Published
- 2022
- Full Text
- View/download PDF
4. Evaluating the cost-effectiveness of a pre-exposure prophylaxis program for HIV prevention for men who have sex with men in Japan
- Author
-
Yamamoto, Nao, Koizumi, Yoshiki, Tsuzuki, Shinya, Ejima, Keisuke, Takano, Misao, Iwami, Shingo, Mizushima, Daisuke, and Oka, Shinichi
- Published
- 2022
- Full Text
- View/download PDF
5. Electrocautery ablation therapy for anal intraepithelial carcinoma: A study protocol
- Author
-
Ando, Naokatsu, Mizushima, Daisuke, Takano, Misao, Kitamura, Hiroshi, Shiojiri, Daisuke, Nakamoto, Takato, Aoki, Takahiro, Watanabe, Koji, Uemura, Haruka, Gatanaga, Hiroyuki, and Oka, Shinichi
- Published
- 2022
- Full Text
- View/download PDF
6. Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan
- Author
-
Shiojiri, Daisuke, Mizushima, Daisuke, Takano, Misao, Watanabe, Koji, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Aoki, Takahiro, Tanuma, Junko, Tsukada, Kunihisa, Teruya, Katsuji, Kikuchi, Yoshimi, Gatanaga, Hiroyuki, and Oka, Shinichi
- Published
- 2021
- Full Text
- View/download PDF
7. Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial.
- Author
-
Ando, Naokatsu, Mizushima, Daisuke, Omata, Kazumi, Nemoto, Takashi, Inamura, Natsumi, Hiramoto, Saori, Takano, Misao, Aoki, Takahiro, Watanabe, Koji, Uemura, Haruka, Shiojiri, Daisuke, Yanagawa, Yasuaki, Tanuma, Junko, Teruya, Katsuji, Kikuchi, Yoshimi, Gatanaga, Hiroyuki, and Oka, Shinichi
- Subjects
HIV-positive persons ,COMBINATION drug therapy ,CLINICAL trials ,PROBENECID (Drug) ,SYPHILIS ,SERODIAGNOSIS ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,COMPARATIVE studies ,RESEARCH funding ,STATISTICAL sampling ,AMOXICILLIN ,PATIENT safety - Abstract
Background Amoxicillin plus probenecid is an alternative to intramuscular benzathine penicillin G for treating syphilis in the United Kingdom. Low-dose amoxicillin is an alternative treatment option used in Japan. Methods We conducted an open-label, randomized, controlled, non-inferiority trial between 31 August 2018, and 3 February 2022, to compare 1500 mg low-dose amoxicillin monotherapy with the combination of 3000 mg amoxicillin and probenecid (non-inferiority margin 10%). Patients with human immunodeficiency virus (HIV) infection and syphilis were eligible. The primary outcome was the cumulative serological cure rate within 12 months post-treatment, measured using the manual rapid plasma reagin card test. Secondary outcomes included safety assessment. Results A total of 112 participants were randomized into 2 groups. Serological cure rates within 12 months were 90.6% and 94.4% with the low-dose amoxicillin and combination regimens, respectively. Serological cure rates for early syphilis within 12 months were 93.5% and 97.9% with the low-dose amoxicillin and combination regimens, respectively. Non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid overall and for early syphilis was not confirmed. No significant side effects were detected. Conclusions This is the first randomized controlled trial to demonstrate a high efficacy of amoxicillin-based regimens for treating syphilis in patients with HIV infection, and the non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid was not seen. Therefore, amoxicillin monotherapy could be a good alternative to intramuscular benzathine penicillin G with fewer side effects. However, further studies comparing with benzathine penicillin G in different populations and with larger sample sizes are needed. Trials Registration (UMIN000033986). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study.
- Author
-
Ando, Naokatsu, Mizushima, Daisuke, Takano, Misao, Mitobe, Morika, Kobayashi, Kai, Kubota, Hiroaki, Miyake, Hirofumi, Suzuki, Jun, Sadamasu, Kenji, Aoki, Takahiro, Watanabe, Koji, Uemura, Haruka, Yanagawa, Yasuaki, Gatanaga, Hiroyuki, and Oka, Shinichi
- Subjects
MYCOPLASMA ,COHORT analysis ,LONGITUDINAL method ,INFECTION ,WORLD health - Abstract
Background Mycoplasma genitalium has a tendency to develop macrolide and quinolone resistance. Objectives We investigated the microbiological cure rate of a 7 day course of sitafloxacin for the treatment of rectal and urogenital infections in MSM. Patients and methods This open-label, prospective cohort study was conducted at the National Center for Global Health and Medicine, Tokyo, Japan from January 2019 to August 2022. Patients with M. genitalium urogenital or rectal infections were included. The patients were treated with sitafloxacin 200 mg daily for 7 days. M. genitalium isolates were tested for parC , gyrA and 23S rRNA resistance-associated mutations. Results In total, 180 patients (median age, 35 years) were included in this study, of whom 77.0% (97/126) harboured parC mutations, including 71.4% (90/126) with G248T(S83I) in parC , and 22.5% (27/120) harboured gyrA mutations. The median time to test of cure was 21 days. The overall microbiological cure rate was 87.8%. The cure rate was 100% for microbes harbouring parC and gyrA WTs, 92.9% for microbes harbouring parC G248T(S83I) and gyrA WT, and 41.7% for microbes harbouring parC G248T(S83I) and gyrA with mutations. The cure rate did not differ significantly between urogenital and rectal infection (P = 0.359). Conclusions Sitafloxacin monotherapy was highly effective against infection caused by M. genitalium , except strains with combined parC and gyrA mutations. Sitafloxacin monotherapy can be used as a first-line treatment for M. genitalium infections in settings with a high prevalence of parC mutations and a low prevalence of gyrA mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men.
- Author
-
Mizushima, Daisuke, Takano, Misao, Aoki, Takahiro, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Watanabe, Koji, Gatanaga, Hiroyuki, Kikuchi, Yoshimi, and Oka, Shinichi
- Published
- 2023
- Full Text
- View/download PDF
10. Identification of asymptomatic Entamoeba histolytica infection by a serological screening test: A cross-sectional study of an HIV-negative men who have sex with men cohort in Japan.
- Author
-
Yanagawa, Yasuaki, Shimogawara, Rieko, Takano, Misao, Aoki, Takahiro, Mizushima, Daisuke, Gatanaga, Hiroyuki, Kikuchi, Yoshimi, Oka, Shinichi, Yagita, Kenji, and Watanabe, Koji
- Subjects
MEN who have sex with men ,ENTAMOEBA histolytica ,SEXUALLY transmitted diseases ,CROSS-sectional method ,POLYMERASE chain reaction - Abstract
Background: Amebiasis, caused by Entamoeba histolytica, is spreading in developing countries and in many developed countries as a sexually transmitted infection. Here, we evaluated the efficacy of serological screening to identify asymptomatic E. histolytica infection as a potential epidemiological control measure to limit its spread. Methodology/Principal findings: This cross-sectional study was carried out between January and March 2021 in an HIV-negative men who have sex with men (MSM) cohort at the National Center for Global Health and Medicine. Serological screening was performed using a commercially available ELISA kit. For seropositive individuals, we performed stool polymerase chain reaction (PCR) to determine current E. histolytica infection. We performed E. histolytica serological screening of 312 participants. None had a history of E. histolytica infection prior to the study. The overall E. histolytica seropositivity was 6.7% (21/312), which was similar to that found by the rapid plasma reagin test (17/312). We identified current infection in 8 of 20 seropositive participants (40.0%) by stool PCR. Conclusions/Significance: Our serological screening approach constitutes a potentially practical epidemiological strategy. Active epidemiological surveys, in combination with an effective screening strategy for asymptomatically infected individuals, should be applied to help reduce sexually transmitted E. histolytica infections. Author summary: Amebiasis, caused by Entamoeba histolytica, is now spreading not only in developing countries, but also in many of developed countries. Unlike the situation in developing countries, transmission occurs directly from one infected person to another via sexual contact, called sexually transmitted E. histolytica infection. Furthermore, most cases of E. histolytica infection are asymptomatic, who can be a reservoir for sexual transmission in the community. Cost-effective epidemiological strategy is urgently needed. Hereby, we performed a serological test for 312 "asymptomatic" HIV-negative men who have sex with men to assess the effective screening method for E. histolytica infection. We identified 21 seropositive samples (6.7% of seropositivity, 21/312), in which relatively high seropositivity to E. histolytica was seen among the participants with positive serology for Treponema pallidum hemagglutination (TPHA) or hepatitis B core antibody (HBcAb). Finally, we identified current infection (asymptomatic E. histolytica infection) in 8 out of 20 stool sampling cases (40.0%) by polymerase chain reaction. Our serological screening assay provides a potentially practical epidemiological strategy. Active epidemiological survey, in combination with the effective screening strategy for asymptomatically infected individuals are considered for the future control of sexually transmitted E. histolytica infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Efficacy of 1 g Ceftriaxone Monotherapy Compared to Dual Therapy With Azithromycin or Doxycycline for Treating Extragenital Gonorrhea Among Men Who Have Sex With Men.
- Author
-
Aoki, Takahiro, Mizushima, Daisuke, Takano, Misao, Ando, Naokatsu, Uemura, Haruka, Yanagawa, Yasuaki, Watanabe, Koji, Gatanaga, Hiroyuki, Kikuchi, Yoshimi, and Oka, Shinichi
- Subjects
EPIDEMIOLOGY of sexually transmitted diseases ,DRUG efficacy ,CEFTRIAXONE ,GONORRHEA ,SCIENTIFIC observation ,PHARYNGEAL diseases ,CONFIDENCE ,CONFIDENCE intervals ,CLINICAL trials ,TIME ,ORAL drug administration ,RECTAL diseases ,DOXYCYCLINE ,FISHER exact test ,COMPARATIVE studies ,MEN who have sex with men ,AZITHROMYCIN ,CHLAMYDIA trachomatis ,DATA analysis software ,LONGITUDINAL method - Abstract
Background Evidence on efficacy of high-dose ceftriaxone monotherapy for extragenital Neisseria gonorrhoeae (NG) infection is lacking. Methods A cohort of men who have sex with men (MSM) were tested for NG/ Chlamydia trachomatis (CT) every 3 months, in a single-center observational study in Tokyo, Japan. MSM aged > 19 years diagnosed with extragenital NG infection between 2017 and 2020 were included. A single dose of 1 g ceftriaxone monotherapy was provided, while dual therapy with a single oral dose of 1 g azithromycin or 100 mg doxycycline administered orally twice daily for 7 days were given, for those coinfected with CT, according to infected sites. Efficacy of these treatments was calculated by the number of NG-negative subjects at test-of-cure divided by the number of subjects treated. Fisher exact tests were used to compare the efficacy between the 2 groups. Results Of 320 cases diagnosed with extragenital NG, 208 were treated with monotherapy and 112 were treated with dual therapy. The efficacy against total, pharyngeal, and rectal infections was 98.1% (204/208, 95% confidence interval [CI]: 95.2–99.3%), 97.8% (135/138, 95% CI: 93.8–99.4%), and 98.6% (69/70, 95% CI: 92.3–99.9%), respectively, in the monotherapy group, whereas the corresponding efficacy in the dual therapy was 95.5% (107/112, 95% CI: 90.0–98.1%), 96.1% (49/51, 95% CI: 86.8–99.3%), and 95.1% (58/61, 95% CI: 86.5–98.7%), respectively. No significant difference in the corresponding efficacy was observed between the two groups (P = .29, P = .61, P = .34, respectively). Conclusions High-dose ceftriaxone monotherapy is as effective as dual therapy for extragenital NG among MSM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Clustering of Polymorphic Membrane Protein E Clade in Chlamydia trachomatis Lineages from Men Who Have Sex with Men.
- Author
-
Mitobe M, Kubota H, Kobayashi K, Miyake H, Takano M, Mizushima D, Gatanaga H, Oka S, Suzuki J, and Sadamasu K
- Subjects
- Humans, Male, Genotype, Bacterial Outer Membrane Proteins genetics, Multilocus Sequence Typing, Polymorphism, Genetic, Chlamydia trachomatis genetics, Chlamydia trachomatis classification, Homosexuality, Male, Chlamydia Infections microbiology, Chlamydia Infections veterinary, Phylogeny
- Abstract
Several Chlamydia trachomatis lineages identified through outer membrane protein A genotyping or multilocus sequence typing have been circulating worldwide among men who have sex with men. In a study in Tokyo, Japan, we demonstrate that such lineages commonly belong to a specific polymorphic membrane protein E clade across genotypes.
- Published
- 2024
- Full Text
- View/download PDF
13. Efficacy and Safety of Pre-Exposure Prophylaxis to Control HIV and Sexually Transmitted Infection Among Men Who Have Sex With Men: Protocol for a Single-Arm Interventional Study.
- Author
-
Terada-Hirashima J, Mizushima D, Takano M, Tokita D, and Oka S
- Abstract
Background: Pre-exposure prophylaxis (PrEP) against HIV infection is a new approach that involves the prophylactic use of the anti-HIV drug Truvada (tenofovir disoproxil fumarate [TDF] and emtricitabine [FTC]) by people not infected with HIV., Objective: The objective of this investigator-initiated clinical study of PrEP was to evaluate the incidence of HIV and sexually transmitted infection (STI), safety and efficacy of PrEP in PrEP users, and their compliance with PrEP medication. The social, medical, and economic benefits of PrEP in Japan was assessed., Methods: This single-center feasibility study of PrEP was conducted at the National Center for Global Health and Medicine, Tokyo, Japan, where a cohort of men who have sex with men without HIV was established in January 2017. This single-arm interventional study compared the efficacy and safety of PrEP in a single group of men who have sex with men who participated in PrEP cohort studies. For reference, the cohort study participants who did not participate in the PrEP study were included for comparison. Blood samples were collected for storage at baseline and clinic visits at 1, 3, and 6 months after starting PrEP and every 3 months thereafter. The participants were administered with 1 tablet of Truvada once daily as PrEP. They underwent blood and anal swab tests 1 and 3 months after starting PrEP and then HIV and STI infection assessments at 3-month intervals. Blood samples were centrifuged at the AIDS Clinical Center Laboratory. PrEP safety was evaluated by monitoring serum creatinine levels for symptoms of renal function disorders. The primary end point was the incidence of HIV in PrEP users (100 person-years). The secondary end points were the incidence of STI in PrEP users (100 person-years), incidence of adverse events caused by Truvada, frequency of high-risk sexual activity, and adherence to periodic visits and medication., Results: The study protocol was reviewed and approved by the certified review board of the National Center for Global Health and Medicine (NCGM-C-003129-03) on April 20, 2020. Changes to the study plan were submitted for review by the certified review board and approved before implementation. Recruitment was completed on March 28, 2019, and the study was completed (last adult participant and last time point) on March 31, 2021. The data were analyzed, and the main results of the study have been published in a peer-reviewed journal., Conclusions: The findings indicated that PrEP is a highly effective and feasible strategy against HIV infection in terms of prophylactic response, retention, and compliance., Trial Registration: UMIN Clinical Trials Registry UMIN000031040; https://tinyurl.com/3msdkeb8 and Japan Registry of Clinical Trials jRCTs031180134; https://tinyurl.com/2p88mhyr., International Registered Report Identifier (irrid): RR1-10.2196/50919., (©Junko Terada-Hirashima, Daisuke Mizushima, Misao Takano, Daisuke Tokita, Shinichi Oka. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 15.11.2023.)
- Published
- 2023
- Full Text
- View/download PDF
14. Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.
- Author
-
Ando N, Mizushima D, Shimizu Y, Uemura Y, Takano M, Mitobe M, Kobayashi K, Kubota H, Miyake H, Suzuki J, Sadamasu K, Nakamoto T, Aoki T, Watanabe K, Oka S, and Gatanaga H
- Abstract
Background: Mycoplasma genitalium is an emerging sexually transmitted pathogen associated with increasing antibiotic resistance. The current treatment guidelines recommend moxifloxacin-sequential therapy for macrolide-resistant Mgenitalium or strains with unknown resistance profiles. However, it is unclear whether sitafloxacin, a 4th-generation fluoroquinolone antibiotic, is effective against resistant strains., Objective: This study aims to assess and compare the efficacy and safety of sitafloxacin- and moxifloxacin-based treatment regimens for managing Mgenitalium infections., Methods: We will conduct this randomized controlled trial at multiple centers in Japan. Eligible participants include adults aged 18 years or older with a confirmed Mgenitalium infection, as determined through the nucleic acid amplification test. Patients will be randomly assigned using a stratified approach based on the treatment facility and infection site. The interventions comprise oral sitafloxacin (200 mg) daily for 7 days (with optional pretreatment of oral doxycycline, 200 mg, daily for up to 7 days), with a control group receiving oral doxycycline (200 mg) daily for 7 days followed by moxifloxacin (400 mg) daily for another 7 days. The primary outcome is the treatment success rate with a superiority margin of 10%, as confirmed through the nucleic acid amplification test. Secondary outcomes encompass changes in the bacterial load at the urogenital or rectal sites and the emergence of posttreatment-resistant mutant strains., Results: Enrollment commenced in June 2023 and will conclude in December 2024, with findings anticipated by 2025. The expected success rates fall within the range of 80% for sitafloxacin and 42% for moxifloxacin against Mgenitalium carrying the G248T (S83I) mutation, based on previous studies. Accordingly, with a 5% significance level (2-sided) and 80% statistical power, we aim to recruit 50 participants per group, factoring in a 10% expected dropout rate., Conclusions: This study will provide valuable insights into the efficacy and safety of sitafloxacin- versus moxifloxacin-based sequential therapy in treating Mgenitalium infections. These findings have the potential to influence clinical guidelines, favoring more effective therapeutic choices. The multicenter approach enhances the robustness of this study. However, a limitation is the potential insufficiency of statistical power to detect posttreatment-resistant mutant strains in each group, rendering posttreatment-resistance mutations a notable concern. In the future, we may need to increase the sample size to enhance power., Trial Registration: Japan Registry of Clinical Trials (jRCTs031230111); https://jrct.niph.go.jp/en-latest-detail/jRCTs031230111., International Registered Report Identifier (irrid): DERR1-10.2196/52565., (©Naokatsu Ando, Daisuke Mizushima, Yosuke Shimizu, Yukari Uemura, Misao Takano, Morika Mitobe, Kai Kobayashi, Hiroaki Kubota, Hirofumi Miyake, Jun Suzuki, Kenji Sadamasu, Takato Nakamoto, Takahiro Aoki, Koji Watanabe, Shinichi Oka, Hiroyuki Gatanaga. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 14.11.2023.)
- Published
- 2023
- Full Text
- View/download PDF
15. Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1.
- Author
-
Kawashima A, Trung HT, Watanabe K, Takano M, Deguchi Y, Kinoshita M, Uemura H, Yanagawa Y, Gatanaga H, Kikuchi Y, Oka S, and Tsuchiya K
- Abstract
Bictegravir (BIC) is an integrase strand transfer inhibitor widely used in the treatment of HIV-1. Although its potency and safety have been demonstrated in older patients, pharmacokinetics (PK) data remain limited in this patient population. Ten male patients aged 50 years or older with suppressed HIV RNA on other antiretroviral regimens were switched to a single-tablet regimen of BIC, emtricitabine, and tenofovir alafenamide (BIC+FTC+TAF). Four weeks later, plasma samples were collected at 9 time points for PK. Safety and efficacy were also assessed up to 48 weeks. The median age (range) of patients was 57.5 (50 to 75) years. Although 8 (80%) had lifestyle diseases requiring treatment, no participants had renal or liver failure. Nine (90%) were receiving dolutegravir-containing antiretroviral regimens at entry. The trough concentration of BIC was 2,324 (1,438 to 3,756) (geometric mean [95% confidence interval]) ng/mL, which was markedly above the 95% inhibitory concentration of the drug (162 ng/mL). All PK parameters, including area under the blood concentration-time curve and clearance, were similar to those in young HIV-negative Japanese participants in a previous study. No correlations between age and any PK parameters were observed in our study population. No participant experienced virological failure. Body weight, transaminase, renal function, lipid profiles, and bone mineral density were unchanged. Interestingly, urinary albumin was decreased after switching. PK of BIC was not affected by age, indicating that BIC+FTC+TAF may be safely used in older patients. IMPORTANCE BIC is a potent integrase strand transfer inhibitor (INSTI), widely used for the treatment of HIV-1 as part of a once-daily single-tablet regimen that includes emtricitabine and tenofovir alafenamide (BIC+FTC+TAF). Although the safety and efficacy of BIC+FTC+TAF have been confirmed in older patients with HIV-1, PK data in this patient population remain limited. Dolutegravir (DTG), an antiretroviral medication with a similar structural formula to BIC, causes neuropsychiatric adverse events. PK data for DTG have shown a higher maximum concentration ( C
max ) among older patients than younger patients and are related to a higher frequency of adverse events. In the present study, we prospectively collected BIC PK data from 10 older HIV-1-infected patients and showed that PK of BIC are not affected by age. Our results support the safe use of this treatment regimen among older patients with HIV-1.- Published
- 2023
- Full Text
- View/download PDF
16. Validation of mailed via postal service dried blood spot cards on commercially available HIV testing systems.
- Author
-
Hayashida T, Takano M, Tsuchiya K, Aoki T, Gatanaga H, Kaneko N, and Oka S
- Abstract
The demand for HIV testing using dried blood spots (DBS) has increased recently. However, DBS is not an approved sample for HIV testing in Japan. This study examined the validation of HIV testing with DBS, prepared at the laboratory or remotely and mailed via postal service to the laboratory. DBS were punched out from a 5.5 mm diameter circle on filter paper, then eluted with 600 μL of phosphate buffered saline overnight at 4℃, and analyzed by Lumipulse S HIVAg/Ab (LUM). The mean LUM count of DBS was 237.4-times diluted compared to titrated plasma. Repeated sample testing showed that although LUM count of DBS decreased slightly with increase in sample storage time (up to one month), it did not affect the result of HIV testing with DBS. Based on testing of 50 HIV+ confirmed cases and 50 HIV- persons, the estimated sensitivity was 98% (49/50) with a specificity of 100% when the cut-off value is 0.5. The single false negative case was a patient with undetectable viral load over the last 10 years, resulting in a decrease of antibody titer below the cut-off level. In conclusion, although DBS cannot completely replace plasma in HIV testing because the sensitivity was a little lower than that of plasma, it can be potentially useful for a screening test by self-finger-prick and postal service use. This will allow people to receive HIV testing without visiting public health centers., Competing Interests: The authors have no conflicts of interest to disclose., (2021, National Center for Global Health and Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.